What happens on November 11?

The investment committee question this week is not whether Democrats will push for ACA subsidy restoration and Medicaid reversal. They will. Democrats broke unified Republican control Tuesday night, winning majorities in both chambers of Congress. Wolfe Research’s Tobin Marcus told CNBC that healthcare will be “the biggest focus,” as Democrats push to restore expired ACA premium subsidies or unwind parts of the Medicaid reforms in the One Big Beautiful Bill Act. The harder question, the one that matters for portfolio managers deciding whether to add here, is whether any of that legislation will reach a bill that gets signed.

The S&P 500 healthcare sector has risen about 20% in 2026 to record highs, trailing only energy. That move did not wait for Tuesday night. Jed Ellerbroek, portfolio manager at Argent Capital Management, told CNBC: “Healthcare stocks have been doing really well lately. Part of that is the anti-AI trade, but I also think part of it is just optimism that Democrats are taking over.” So the sector was already pricing election optimism. Now it has the election result, and the question is what the result is actually worth.

The Veto Problem

The honest answer from the buy side is: less than the market may assume. President Trump’s veto authority would still constrain the advancement of major partisan legislation, making a wholesale reversal of the administration’s healthcare agenda unlikely. JPMorgan Asset Management’s Tai Hui noted that “Trump still has veto power,” and overriding that veto requires two-thirds of each chamber. Democrats do not have that. Hui rated a full return of expanded ACA subsidies as less likely than a delay to Medicaid cuts. That is a meaningful distinction for the managed-care names.

Trump has already said he may veto a bill to extend ACA subsidies if Congress sent one to his desk. Democrats’ primary leverage runs through must-pass spending bills and a debt-ceiling deadline, not through standalone healthcare legislation that the White House has consistently opposed. The gap between what Democrats can pass and what becomes law is the gap the market has not fully reckoned with.

Who Benefits, and Who Has Already Run

Hospitals and Medicaid-focused insurers split into two different stories here. On the hospital side, Jefferies named HCA Healthcare, Tenet Healthcare, Community Health Systems and Acadia Healthcare as hospital stocks that could benefit from a Democratic win. Tenet is up roughly 38% year to date. That is not a stock sitting in the shadows waiting for a catalyst. Tenet and peers have flagged meaningful 2026 headwinds from the expiration of enhanced premium tax credits. Restoration would directly reverse that drag, but restoration requires Trump’s signature.

HCA’s policy exposure is only part of the story. HCA has been deploying AI scheduling tools to cut labor costs independent of any subsidy outcome, which matters for investors weighing the stock’s floor if legislative relief stalls.

On the managed-care side, the picture is thornier. Molina Healthcare reported about $43.1 billion of premium revenue in 2025, with Medicaid as its largest line of business, and warned in its annual SEC filing that losing government contracts or renewing them on worse terms could materially reduce premium revenue. Magdalena Ocampo of Principal Asset Management told Reuters that a Democratic sweep “could create greater momentum behind measures targeting healthcare costs,” which includes drug pricing pressure on insurers’ pharmacy benefit businesses. UNH and CVS carry that exposure. Centene is up roughly 64% year to date, while UNH has gained about 22.5% and CVS roughly 15%.

What the Committee Is Missing

Democrats will have substantially greater leverage over appropriations and FDA user-fee reauthorization and other must-pass legislation. That is the overlooked mechanism. The more credible near-term path is not a clean ACA bill signed into law. It is Medicaid cut delays embedded in a government funding deal, extracted as part of a year-end spending negotiation. Congress will return for a year-end session with a to-do list that includes funding the federal government for fiscal year 2027 and multiple expiring healthcare provisions. That lame-duck window is where the real bargaining happens.

CVS carries its own exposure to this policy moment. CVS Health’s distribution relationship with McKesson runs through 2032, locking in a cost structure that drug-pricing pressure from a Democratic Congress could stress.

Stocks to Watch

• HCA Healthcare (HCA): The largest U.S. hospital operator is the most direct beneficiary of restored exchange coverage. HCA earlier this year cut its full-year profit outlook after treating more uninsured patients who lost coverage when ACA subsidies lapsed. Any partial restoration changes that payer-mix math in the company’s favor.
• Tenet Healthcare (THC): Up more than 38% in 2026 and already baking in the recovery story. The stock carries a high earnings multiple relative to peers and would need actual legislative progress, not just Democratic control, to justify further premium from here.
• Molina Healthcare (MOH): With Medicaid as its largest line of business, MOH has high direct exposure to any rollback of the 2025 cuts. It is the clearest beneficiary if spending negotiations produce even a partial delay, and the stock is up roughly 20% year to date, leaving some room for surprise.
• Centene (CNC): ACA marketplace enrollment and premium subsidy levels directly affect Centene’s membership and premium revenue in states where it participates. With the stock up more than 60% in 2026, the good news may be priced, but any actual subsidy legislation would be a second-leg catalyst.

The sector at record highs with a veto-constrained Congress is a different risk/reward than the sector at record highs with a friendly White House. The smartest money in this committee is probably not adding broad healthcare exposure today. It is picking the specific names whose 2026 guidance was written assuming no policy relief, and where even a partial deal resets estimates upward.